Trustees’ Annual Report for the period
From 1[st] January 2025 To 31[st] December 2025
Charity name: Salivary Gland Cancer UK
Charity registration number: 1182762
Objectives and Activities
| SORP reference | ||
|---|---|---|
| Summary of the purposes of the charity as set out in its governing document |
Para 1.17 | Help those affected by rare salivary gland cancers. Advocate for these patients and carers by providing peer support and information about their disease, care and treatment. Promote and assist research into all aspects of salivary gland cancers, including causes, diagnosis, treatments and cures. To educate the public and healthcare communities in all things related to salivary gland cancers, including raising awareness of symptoms. |
| Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts. |
Para 1.17 and 1.19 |
• Supporting the community via in person and virtual meetings for patients, carers and clinicians. • Providing information and increasing awareness via leaflets, meetings, the website, social media and fundraising events. • Raising awareness of these cancers and their unmet need via speaking, submitting materials and attending meetings and conferences. • Expansion of the network to support all salivary gland cancer types. • Expansion of the charity’s outputs to provide more research and disease specific information. |
| Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit |
Para 1.18 | The trustees have kept in mind the charity Constitution and the guidance from the Charities Commission in all of its’ activities. The governance documents of the Charity are regularly reviewed at Trustee meetings. |
1
The charity’s “8 aims” are regularly published via our social media outlets and are the foundation for all activities and decisions within the charity. The trustees ensure the prioritisation of activities is aligned with these aims.
Additional information (optional) You may choose to include further statements where relevant about:
| SORP reference | ||
|---|---|---|
| Policy on grant making | Para 1.38 | We invest directly in research infrastructure. Our first grant call funded projects mapping the pathway to diagnosis and developing guidance to support earlier detection. We have supported the rollout of a UK-wide surgical registry, which collects clinical and patient-reported outcomes data to improve understanding of treatment outcomes and disease progression. We also rolled out our very first travel grant so our community can apply for financial support to travel to a relevant conference or workshop that is aligned with our strategy as a charity. This is available to those who do not otherwise receive funding to attend such events e.g. medical undergraduates, allied healthcare professionals and patient advocates. |
| Policy on social investment including program related investment |
Para 1.38 | |
| Contribution made by volunteers |
Para 1.38 | We are hugely grateful for the continued support and contribution we received from our volunteers assisting us in specific projects and outputs, sharing their stories on social media channels, and ‘on the day’ physical support at both our own events and conferences we attend. |
| Other |
2
Achievements and Performance
| SORP reference | ||
|---|---|---|
| Summary of the main achievements of the charity, identifying the difference the charity’s work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole. |
Para 1.20 | Launch of annual Salivary Gland Cancer Day – 4th October 2025 SGC Day was launched on 4 October 2025 at Manchester Art Gallery - the first awareness day dedicated to these cancers in the UK. The initiative was created to address a major barrier to progress: the lack of public and professional awareness surrounding salivary gland cancers. Through coordinated social media campaigns, patient storytelling and community engagement, the day brought unprecedented visibility to SGCUK and these rare diseases. Patients, clinicians and supporters across the UK and internationally participated. Social media posts were created in 25 languages ensuring as wide a reach as possible. The success of the inaugural annual awareness day has established a powerful platform for future national awareness campaigns. Bringing together those living with salivary gland cancers We continued to host bi-annual hybrid (in person/virtual) meetings during 2025, supporting attendees with travel bursaries for patients and their carers where needed. The hybrid structure of our events has facilitated strong attendance from our community across the country and internationally. In May 2025 we hosted a gathering in Sheffield and October 2025’s event was in Manchester. We provided regular communications, newsletters and updates to the network. We continued to produce our video series, releasing recordings of the presentations at our hybrid meetings to ensure we reach as many people as possible. We also continued to add patient stories on social media and on our website. We also hosted a number of ‘stop by’ sessions online where the community could |
3
| drop in for a chat with members of our team |
|---|
| about anything they wanted to discuss. |
| Raising awareness amongst the general |
| public and the clinical community |
| We continue to work to increase our visibility |
| among the clinical and patient network by |
| attending and presenting at various |
| conferences and events. |
| In March we attended ESMO Rare Cancers |
| Congress where Dr Metcalf delivered a |
| presentation on behalf of the UK Salivary |
| Gland Cancer Research Working Group |
| (UKSGCRWG), titled “Advancing Salivary |
| Gland Cancer Research: A Multidisciplinary |
| Approach to Addressing the Unmet Clinical |
| Need.” |
| In June, we chaired a panel discussion at |
| the inaugural National Patient Data Day, |
| hosted by use MY data, delving into the |
| critical question: 'Can we create a UK-wide |
| data environment fit for international rare |
| disease research?' |
| In July we attended IAOO2025, where we |
| had a stall and our CEO Dr Emma Kinloch |
| delivered a keynote speech on patient |
| voices in research. IAOO 2025 is the 10th |
| World Congress of the International |
| Academy of Oral Oncology, bringing |
| together over 1,000 delegates from various |
| disciplines involved in oral cancer care. |
| We attended the Swallows Head and Neck |
| Conference in November to ensure SGC |
| patient needs are represented in |
| discussions on the latest surgical and |
| radiotherapy treatments. |
| We also joined the Cancer Drug |
| Development Forum (CDDF) workshop in |
| November, titled "Enabling Smarter Clinical |
| Trials to Optimise Patient Care." |
| Our Patient and Public Involvement (PPI) |
| work has continued to grow and develop in |
| 2025. We are regularly called upon to input |
| into the design of research studies, provide |
| feedback on trial protocols, help researchers |
| develop lay summaries of their work and |
| bring the perspective of those with lived |
| experiences to discussions. |
4
| Many fundraising events, both large and |
|---|
| small, have taken place during the year, |
| notably our supporters’ participation in the |
| London and Loch Ness Marathons and The |
| Big Half in London. |
| Bringing together the patient, clinical |
| and research communities to help drive |
| forward research and improvements in |
| treatments |
| Our Research Working Group has been |
| very active during 2025. Consisting of |
| clinicians, researchers and patient |
| advocates from all around the UK and |
| beyond. |
| The group meets twice a year in full with 4 |
| separate workstreams meeting throughout |
| the year to focus on their individual topics in |
| line with the charity’s aims. |
| Our involvement on the PRONTO trial |
| management committee continued as it |
| opened for recruitment at The Christie and |
| UCLH, representing a significant step |
| forward in optimising care for Salivary Gland |
| Cancer. The primary focus of this study is on |
| patient quality of life. |
Additional information (optional) You may choose to include further statements where relevant about:
Achievements against Para 1.41 objectives set Performance of fundraising Para 1.41 activities against objectives set Investment performance Para 1.41 against objectives Other
5
Financial Review
| Financial Review | ||
|---|---|---|
| Review of the charity’s financial position at the end of the period |
Para 1.21 | As at 31stDecember 2025 the charity held a cash balance of £50,077, (prior year £68,381). The charity had an in-year deficit of £18,304 (prior year deficit £36,451). The charity received income of £39,609 (prior year £37,336) from donations raised through fund raising initiatives and personal legacies. The charity’s accounts for the year have been independently reviewed with no issues raised. Despite an in-year deficit, the charity’s financial position remains robust. There are substantial fundraising activities planned for 2026 and we are predicting an in-year surplus. |
| Statement explaining the policy for holding reserves stating why they are held |
Para 1.22 | The cash balance is held in order to support the overall objectives of the charity. Cash is used to cover operating expenses, develop the charity’s presence through marketing and fund specific patient/clinician events. Cash held is also the source funds for the grants we have issued and for any other grant making opportunities that may arise. |
| Amount of reserves held | Para 1.22 | £50,077 in cash. |
| Reasons for holding zero reserves |
Para 1.22 | Not applicable |
| Details of fund materially in deficit |
Para 1.24 | Not applicable |
| Explanation of any uncertainties about the charity continuing as a going concern |
Para 1.23 | There are no uncertainties around the charity’s ability to continue as a going concern. The Board, together with the CEO, carefully consider the on-going running costs of the charity when assessing the funds available for grants and other events. |
| Additional information (optional) You may choose to include further statements |
Additional information (optional) You may choose to include further statements |
where relevant about: |
|---|---|---|
| The charity’s principal sources of funds (including any fundraising) |
Para 1.47 | |
| Investment policy and objectives including any social investment policy adopted |
Para 1.46 | |
| A description of the principal risks facing the charity |
Para 1.46 | The Board maintains a Risk Register for the charity. This document highlights governance, operational, financial, compliance and external risks and the mitigants in place. The Board reviews the Risk Register periodically. |
| Other |
6
Structure, Governance and Management
| Description of charity’s trusts: |
||
|---|---|---|
| Type of governing document (trust deed, royal charter) |
Para 1.25 |
The charity is governed by its Constitution. |
| How is the charity constituted? (e.g unincorporated association, CIO) |
Para 1.25 | The charity is a Charitable Incorporated Organisation. |
| Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees |
Para 1.25 | Trustees must be appointed for a term by a resolution passed at a properly convened meeting of the charity trustees. When selecting trustees, the charity trustees have regard to the skills, knowledge and experience needed for the effective administration of the CIO. The Board periodically reviews a detailed skills matrix to identify any gaps and regularly discusses the structure and composition of the Board to ensure its ongoing effectiveness as a governing body. |
Additional information (optional) You may choose to include further statements where relevant about:
| Policies and procedures adopted for the induction and training of trustees |
Para 1.51 | All new trustees undertake an induction process which includes receiving an induction pack containing relevant policies, procedures and key organisational information, together with an individual meeting with the CEO. Prospective trustees are also invited to attend Board meetings as observers prior to their formal appointment, enabling them to gain an understanding of the charity’s governance, operations and responsibilities of trustees. Ongoing training and development needs are identified as appropriate throughout their tenure. |
|---|---|---|
| The charity’s organisational structure and any wider network with which the charity works |
Para 1.51 | |
| Relationship with any related parties |
Para 1.51 | |
| Other |
7
Reference and Administrative details
| Charity name | Salivary Gland Cancer UK |
|---|---|
| Other name the charity uses | |
| Registered charity number | 1182762 |
| Charity’s principal address | International House 36-38 Cornhill City of London London EC3V 3NG |
8
Names of the charity trustees who manage the charity
| 1 2 3 4 5 6 |
Trustee name | Office (if any) | Dates acted if not for whole **year ** |
Name of person (or body) entitled to appoint trustee (ifany) |
|---|---|---|---|---|
| Dr Robert Metcalf | Trustee | The Board | ||
| Shane Lisa Draper | Trustee and Chief Financial Officer |
The Board | ||
| Olorunkemi Fausat Akanke Olaiya |
Treasurer | **Non-Board role | The Board | |
| Jacqueline O’Connor |
Chair of Board | Start date – December 2025 |
The Board | |
| Sally Crowe | Trustee | Start date – December 2025 |
The Board | |
| Barry Thomas | Trustee | Start date – December 2025 |
The Board | |
– Corporate trustees names of the directors at the date the report was approved
Director name
Name of trustees holding title to property belonging to the charity
Trustee name Dates acted if not for whole year
9
Funds held as custodian trustees on behalf of others
Description of the assets Not applicable held in this capacity Name and objects of the Not applicable charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for Not applicable safe custody and segregation of such assets from the charity’s own assets
Additional information (optional)
Names and addresses of advisers (Optional information)
| Type of | Name | Address |
|---|---|---|
| adviser |
Name of chief executive or names of senior staff members (Optional information)
Dr Emma Kinloch - CEO
Exemptions from disclosure
Reason for non-disclosure of key personnel details
Other optional information
10
Declarations
The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees
| Signature(s) Full name(s) Position (eg Secretary, Chair, etc) Date |
||
|---|---|---|
| Jacqueline O’Connor | Shane Lisa Draper | |
Chair of the Board of Trustees |
Chief Financial Officer | |
| 19.10.26 19.10.26 |
||
| 19.10.26 |
11
| Salivary Gland Cancer UK |
Salivary Gland Cancer UK |
Salivary Gland Cancer UK |
No (if any) 1182762 |
CC16a | |
|---|---|---|---|---|---|
| Receipts and payments accounts | |||||
| For the period from |
Period start date 1st January 2025 |
To | Period end date 31st December 2025 |
||
| Section A Receipts and payments | |||||
| A1 Receipts | Unrestricted funds to the nearest £ 35,740 2,197 - 384 325 964 - - - - 39,609 |
Restricted funds to the nearest £ |
Endowment funds to the nearest £ |
Total funds to the nearest £ |
Last year to the nearest £ |
| Donations via Just Giving, Easy Fundraising, Paypal and otherplatforms |
- - - - - - - - - - |
- | 35,740 | 24,029 | |
| Donations received from organisations/individuals |
- | 2,197 | 11,183 | ||
| Grants from organisations/collaboration agreements |
- | - | 840 | ||
| Shop income | - | 384 | - | ||
| Other income | - | 325 | - | ||
| Bank interest | - | 964 | 1,285 | ||
| - | - | - | |||
| - | - | - | |||
| - | - | - | |||
| - | - | - | |||
| Sub total(Gross income for AR) | - | - | 39,609 | 37,336 |
A2 Asset and investment sales, (see table).
| Sub total(Gross income for AR) | Sub total(Gross income for AR) | Sub total(Gross income for AR) | Sub total(Gross income for AR) | Sub total(Gross income for AR) | Sub total(Gross income for AR) |
|---|---|---|---|---|---|
| A2 Asset and investment sales, **(see table). ** |
|||||
| - - |
- - |
- | - | ||
| - | - | - | |||
| Sub total | - |
- | - | - | - |
| Total receipts A3 Payments |
37,807 17,112 124 665 1,270 936 - - - 57,913 |
||||
| - | - | 39,609 | 37,336 | ||
| Charity admin expenses and running costs | - - - - - - - - - |
- | 37,807 | 33,073 | |
| In person meeting expenses e.g. room hire | - | 17,112 | 17,379 | ||
| Bursaries for attendees | - | 124 | 508 | ||
| Memberships and collaborative expenses | - | 665 | 316 | ||
| Entry into events for members fundraising | - | 1,270 | 1,510 | ||
| Grants | - | 936 | 21,000 | ||
| - | - | - | |||
| - | - | - | |||
| - | - | - | |||
| Sub total | - | - | 57,913 | 73,787 |
A4 Asset and investment purchases, (see table)
| A4 Asset and investment purchases, (see table) |
A4 Asset and investment purchases, (see table) |
A4 Asset and investment purchases, (see table) |
A4 Asset and investment purchases, (see table) |
A4 Asset and investment purchases, (see table) |
A4 Asset and investment purchases, (see table) |
|---|---|---|---|---|---|
| - | - | - | - | ||
| - | - | - | - | ||
| Sub total | - |
- | - | - | - |
| Total payments Net of receipts/(payments) A5 Transfers between funds A6 Cash funds last year end Cash funds this year end |
|||||
| - | - | 57,913 | 73,787 | ||
| (18,304) | - | - | - 18,304 |
- 36,451 |
|
| - | - | - | - | - | |
| 68,381 50,077 |
- | - | 68,381 | 104,832 | |
| - | - | 50,077 | 68,381 | ||
| Section B Statement of assets and liabilities at the end of the period | |||||
| Categories B1 Cash funds |
Details Bank account balance (Lloyds) Notice account (Lloyds) |
Unrestricted funds to nearest £ 16,268 32,856 |
Restricted funds to nearest £ |
Endowment funds to nearest £ - - |
|
| - - |
| 953 | - | - | ||||
|---|---|---|---|---|---|---|
| 50,077 | - | - | ||||
| OK | OK | OK | ||||
| Unrestricted funds to nearest £ Fund to which asset belongs - - - - - - |
Restricted funds to nearest £ Cost (optional) - - - - - - |
Endowment funds to nearest £ |
||||
| - | ||||||
| - | ||||||
| - | ||||||
| - | ||||||
| - | ||||||
| - | ||||||
| Current value (optional) |
||||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| Current value (optional) |
||||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| When due (optional) | ||||||
| - | ||||||
| - | ||||||
| - | ||||||
| - | ||||||
| - | ||||||
| Date of approval | ||||||
| 19.10.26 | ||||||
| 19.10.26 | ||||||
Shane Draper
CHARITY COMMISSION FOR ENGLAND AND WALES Independent examiner's report on the accounts Report to the trusteesl members of Salivary Gland Cancer UK On accounts for the year ended 31" December 2025 Charfty no (if any) 1182762 Set out on pages I report lo the trustees on my examination of the accounts ofthe above charity ('the Trust") for the year ended 31st December 2025. Responsibilities and As the charity trustees of the Trust, you are responsible for the preparation basis of report of the accounts in accordance with the requirements of the Charits'es Act 20111.the ACV'I. I report in respect of my examination of the Trust's accounls carried out under section 145 of the 2011 Act and in carying oul my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(bl of the Act. I have Gompleted my examination. I confirm that no material matters have come to my attention (other than that disclosed below ') in conneclion with the examination which gives me cause to believe that in, any rnaterial respect= accounting records were not kept in accordan with section 130 of the Act or the accounts do not accord with the accounting records Independent examinerfs statement I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached. Please delete the words in the brackets if they do not apply. Signed: Date: Name: Mrs Karen Wicks Relevant professTonal qualification(sl or body (rf any): Accountant Address: On request IER October 2018
Only complete ifthe examiner needs lo highlight matters of Goncern (see CC32, Independent examination of charity accoLsnts.' directions and guidance for exarniners). Give here brief details of any items that the examlner wishes to disclose. IER October 2018